Fig. 1From: The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trialMean (SE) changes from baseline in MBDA score and DAS28 for each strategy arm of the CAMERA-II study. Mean (SE) changes from baseline in MBDA score and DAS28 for each strategy arm of the CAMERA-II study are shown over first 5Â months at monthly assessments, each prior to dosing with MTX and placebo (MTX+plac) or MTX and prednisone (MTX+pred) at that time-point. P values of t tests for comparison between strategy arms (Group diff). Patient numbers are shown for each time-point in each strategy armBack to article page